Lanraplenib succinate (GS-9876 succinate) is primarily investigated for its potential in treating autoimmune diseases and hematologic malignancies. It functions as an inhibitor of spleen tyrosine kinase (SYK), a key enzyme involved in signaling pathways that regulate immune responses and cancer cell proliferation. In clinical studies, it has shown promise in managing conditions like rheumatoid arthritis, systemic lupus erythematosus, and certain types of leukemia by modulating immune system activity and reducing inflammation. Its application is particularly focused on patients who do not respond adequately to conventional therapies, offering a targeted approach to improve treatment outcomes. Ongoing research aims to further explore its efficacy and safety in broader therapeutic contexts.